Ulusal Romatoloji Dergisi / Journal of Turkish Society for Rheumatology
 
 
p-ISSN: 2651-2653
e-ISSN: 2651-2661
Editor-in-Chief
Haner Direskeneli
2019 Volume 11
 
 
Deomed Yayıncılık
 
 
 
Volume 10, Issue 1, June 2019
Page(s): 1-9
 
Clinical Research Article
Received: March 18, 2018; Accepted: March 18, 2018; Published online: June 10, 2019
doi:10.2399/raed.19.99608; Copyright © 2019 Turkish Society for Rheumatology
Switching between biological DMARDs and associated reasons in rheumatoid arthritis and spondyloarthritis treatments: TReasure study-real life data
Umut Kalyoncu1 (E-mail), Ali İhsan Ertenli1, Orhan Kücükşahin2, Hüseyin Ediz Dalkılıç3, Abdulsamet Erden4, Cemal Bes5, Nilüfer Alpay Kanıtez6, Timuçin Kaşifoğlu7, Pınar Kızılırmak8, Hakan Emmungil9, Belkis Nihan Coşkun10, Burcu Yağız3, Süleyman Serdar Koca11, Muhammet Çınar12, Aşkın Ateş13, Servet Akar14, Duygu Ersözlü15, Veli Yazısız16, Nazife Şule Yaşar Bilge7, Gezmiş Kimyon17, Müge Aydın Tufan18, Rıdvan Mercan19, Emel Gönüllü20, Emre Tekgöz12, Ömer Karadağ1, Ayşe Bahar Keleşoğlu Dinçer13, Sedat Yılmaz12, Yavuz Pehlivan3, Önay Gerçik14, Burak Öz11, Mustafa Ender Terzioğlu16, Levent Kılıç1, Şükran Erten4, Sedat Kiraz1, TReasure Çalışma Grubu
1Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey; 2Rheumatology Clinic, Ankara Liv Hospital, Ankara, Turkey; 3Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Uludağ University, Bursa, Turkey; 4Outpatient Rheumatology Clinic, Turkish Ministry of Health Atatürk Training and Research Hospital, Ankara, Turkey; 5Rheumatology Clinic, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey; 6Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Koç University, Istanbul, Turkey; 7Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Osmangazi University, Eskişehir, Turkey; 8Meical Manager, Amgen Turkey, Istanbul, Turkey; 9Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey; 10Rheumatology Clinic, Turkish Ministry of Health İlker Çelikcan Physical Therapy and Rehabilitation Hospital, Bursa, Turkey; 11Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fırat University, Elazığ, Turkey; 12Rheumatology Clinic, Turkish Ministry of Health Health Sciences University Gülhane Training and Research Hospital, Ankara, Turkey; 13Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey; 14Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, İzmir Kâtip Çelebi University, Izmir, Turkey; 15Rheumatology Clinic, Turkish Ministry of Health Adana Training and Research Hospital, Adana, Turkey; 16Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Akdeniz University, Antalya, Turkey; 17Division of Rheumatology, Department of Internal Medicine, Tayfur Ata Sökmen Faculty of Medicine, Mustafa Kemal University, Antakya, Turkey; 18Division of Rheumatology, Department of Internal Medicine, Başkent University Adana Application and Research Hospital, Adana, Turkey; 19Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Namık Kemal University, Tekirdağ, Turkey; 20Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Sakarya University, Sakarya, Turkey
Summary
Objective: To determine features of patients switching between biological (b) DMARDs in rheumatoid arthritis (RA) and spondyloarthritis (SpA) treatments and to investigate associated reasons.

Methods: This multicenter, prospective, observational cohort study used the TReasure database in which web-based registration of RA and SpA patients are being performed in 15 centers across Turkey. In this study, switching rates between bDMARDs, associated reasons, and features were analyzed in patients continuing bDMARD treatments during their follow-up periods.

Results: Analysis included 2115 RA patients and 3138 SpA patients, of whom 829 (39.2%) RA and 1165 (37.1%) SpA patients switched to another bDMARD and 1286 (60.8%) RA and 1973 (62.9%) SpA patients continued to receive their current therapies (continued group). Median follow-up duration was 3.7 (range: 0-58.4) years in RA patients and 3.8 (range: 0-45.1) years in SpA patients. Female proportion was higher in both RA and SpA patients in the switched group. The first bDMARD used was an anti-TNF in 60.9% of RA patients and another bDMARD in 39.1%. According to switching patterns between bDMARDs, of RA patients, 41% switched from one anti-TNF to another and 38.4% switched from one anti-TNF to a bDMARD with other mechanism of action. The main reasons for switching in both RA and SpA patients were primary or secondary ineffectiveness and side effects.

Conclusion: Further data on compliance to bDMARD treatment and treatment discontinuation or switching from one bDMARD to another in rheumatologic patients are needed to improve outcomes of patients and to ensure rational use of health expenditures.
Keywords: Rheumatoid arthritis, spondyloarthritis, biological DMARD, anti-TNF
 
 
Reklam
 
   
RAED Dergisi / RAED Journal

Türkiye Romatoloji Derneği (TRD) yayın organıdır. Deomed Yayıncılık tarafından yayımlanmaktadır. / Official Publication of the Rheumatology Society of Turkey (TRD). Published by Deomed Publishing. Copyright © 2019, TRD.
Creative Commons License
RAED Dergisi çevrimiçi (online) sürümünde yayımlanan akademik içeriğin kullanım hakları, ilgili içerikte tersi belirtilmediği sürece Deomed Yayıncılık tarafından Creative Commons Attribution-NoCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) lisansı aracılığıyla bedelsiz sunulmaktadır. / Except where otherwise noted, academic content of this online version of the journal by Deomed Publishing is licensed under the terms of Creative Commons Attribution-NoCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) License.